Literature DB >> 375794

Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin.

R L Schilsky, T Anderson.   

Abstract

We studied renal function and serum electrolytes in 51 patients receiving cisplatin chemotherapy by retrospectively reviewing the charts of 44 patients and prospectively following seven patients. Hypomagnesemia developed in 23 of 44 evaluable patients who were receiving cisplatin. We documented inappropriate renal magnesium wasting in four patients. Two patients required hospitalization for symptomatic hypomagnesemia. We conclude that cisplatin can induce a renal tubular defect in magnesium conservation and serious clinical syndromes of magnesium deficiency.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 375794     DOI: 10.7326/0003-4819-90-6-929

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  49 in total

Review 1.  Cisplatin nephrotoxicity. A review.

Authors:  G Daugaard; U Abildgaard
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 2.  Drug-induced hypomagnesaemia : scope and management.

Authors:  Jacob Atsmon; Eran Dolev
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Cisplatin therapy-associated recurrent toxic shock syndrome.

Authors:  A C Berman; L R Boly
Journal:  West J Med       Date:  1991-10

4.  Effect of silymarin in the prevention of Cisplatin nephrotoxicity, a clinical trial study.

Authors:  Ali Momeni; Ali Hajigholami; Shohreh Geshnizjani; Soleiman Kheiri
Journal:  J Clin Diagn Res       Date:  2015-04-01

5.  Reply to L.H. Einhorn et al.

Authors:  Deaglan McHugh; George J Bosl; Samuel A Funt; Darren R Feldman
Journal:  J Clin Oncol       Date:  2020-07-07       Impact factor: 44.544

6.  Acute and long-term nephrotoxicity of cis-platinum in man.

Authors:  S Groth; H Nielsen; J B Sørensen; A B Christensen; A G Pedersen; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  Cisplatin-induced gastric paresis.

Authors:  S C Cohen; J E Mollman
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

8.  Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines.

Authors:  Ti Zhang; Shuang Cai; Chad Groer; Wai Chee Forrest; Qiuhong Yang; Eva Mohr; Justin Douglas; Daniel Aires; Sandra M Axiak-Bechtel; Kimberly A Selting; Jeffrey A Swarz; Deborah J Tate; Jeffrey N Bryan; M Laird Forrest
Journal:  J Pharm Sci       Date:  2016-05-04       Impact factor: 3.534

9.  Lack of effect of oral magnesium on high blood pressure: a double blind study.

Authors:  F P Cappuccio; N D Markandu; G W Beynon; A C Shore; B Sampson; G A MacGregor
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-27

10.  Evaluation of intervention to prevent hypomagnesemia in cervical cancer patients receiving combination cisplatin and radiation treatment.

Authors:  Rodney J Hunter; Makala B Pace; Kimberly A Burns; Catherine C Burke; Deborah A Gonzales; Nicki F Webb; Charles F Levenback; Anuja Jhingran; Crystal Parker; Mark F Munsell; Judith A Smith
Journal:  Support Care Cancer       Date:  2009-01-27       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.